Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTPRB | P23467 | 1/20 | 0.33 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 5/20 | 0.33 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.33 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.33 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 6/20 | 0.32 |
| ▸ | CHRM3 | P20309 | 6/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 4/20 | 0.32 |
| ▸ | CHRM5 | P08912 | 4/20 | 0.32 |
| ▸ | F2 | P00734 | 2/20 | 0.32 |
| ▸ | UTS2R | Q9UKP6 | 1/20 | 0.31 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.31 |
| ▸ | PDE5A | O76074 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15397603 | 0.83 | TACR1 (0.37) | PTPRBPTPN11SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1969398 | 0.81 | LMNA (0.37) | SLC6A2SLC6A4SLC6A3UTS2R | |
| SCHEMBL30693198 | 0.81 | PTPRB (0.41) | PTPRBPTPN11 | |
| SCHEMBL1974693 | 0.81 | PTPRB (0.41) | PTPRBPTPN11 | |
| SCHEMBL1972616 | 0.73 | SLC6A4 (0.35) | SLC6A2SLC6A4SLC6A3PDE5A | |
| SCHEMBL1971001 | 0.73 | SLC6A4 (0.37) | SLC6A2SLC6A4SLC6A3PDE5A | |
| SCHEMBL1973935 | 0.69 | TACR1 (0.43) | — | |
| SCHEMBL1972983 | 0.69 | TACR1 (0.38) | — | |
| SCHEMBL1970342 | 0.68 | TACR1 (0.42) | — | |
| SCHEMBL1968593 | 0.67 | TACR2 (0.38) | SLC6A2SLC6A4SLC6A3PDE5A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2011-07-21 | — | — | US | disclosed |
| EP-2336105-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | Takeda Pharmaceutical Company Limited (JP) | 2011-06-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178060-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND AND USE OF SAME | NTSR2, BDKRB1, AVPR1B | PTPRB 3735/4885PTPN11 1915/4885ACHE 1659/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.